Taken together, the results indicate that RN181 suppresses the tumour growth of GC by inhibition of the ERK/MAPK pathway and consequently control of the activity of cyclin D1–CDK4 that regulates the cell cycle transition from G1 to S phase. Here, CDK4 is linked to neoplasm.